Sylics
InnoSer Laboratories is a global preclinical CRO and research partner dedicated to advancing biomedical research through innovative services, tailored models, and collaborative approaches. Originating as a mouse model breeding facility in 2012, InnoSer has grown into a comprehensive research organization supporting neurology, oncology, immunology, nephrology, cardiology, metabolic diseases, and rare genetic disorders. They offer a wide range of services including target validation, hit to lead, lead optimization, preclinical development, pathology, facility management, and custom model development. With a strong commitment to animal welfare and the 3Rs principles, InnoSer maintains AAALAC accreditation in the Netherlands and Belgium. The company actively participates in international consortia and industry-funded projects to develop innovative models such as PDX, PDO, organ-on-chip, and AI-integrated platforms. InnoSer’s leadership team includes CEO Kris Motmans, PhD, and CSO Yanick Fanton, PhD, supported by a team of principal scientists and dedicated study directors. They emphasize flexible, transparent, and high-quality research solutions to accelerate drug development and bring therapies to patients sooner.
Industries
Nr. of Employees
small (1-50)
Products
Validated disease model portfolios
Catalogs of validated preclinical models (rodent, organoid and ex vivo systems) across neurology, oncology, immunology, nephrology, metabolic and cardiovascular research, provided with model validation data and standardized readouts.
Integrated PDO/PDX screening platform and biobank
An integrated platform combining patient-derived organoid (PDO) screening and patient-derived xenograft (PDX) in vivo testing with a commercial biobank of characterized models for translational drug screening and validation.
ADPKD mouse model and validated readout package
Inducible, kidney-specific conditional knockout mouse models with staged disease progression options and a validated readout package including cystic index, ultrasound kidney volume, transdermal GFR and histopathology for nephrology research.
Validated disease model portfolios
Catalogs of validated preclinical models (rodent, organoid and ex vivo systems) across neurology, oncology, immunology, nephrology, metabolic and cardiovascular research, provided with model validation data and standardized readouts.
Integrated PDO/PDX screening platform and biobank
An integrated platform combining patient-derived organoid (PDO) screening and patient-derived xenograft (PDX) in vivo testing with a commercial biobank of characterized models for translational drug screening and validation.
ADPKD mouse model and validated readout package
Inducible, kidney-specific conditional knockout mouse models with staged disease progression options and a validated readout package including cystic index, ultrasound kidney volume, transdermal GFR and histopathology for nephrology research.
Services
Breeding, housing, genotyping, cryopreservation, rederivation and long-term storage of rodent lines under SPF conditions and FELASA guidance; services operate within AAALAC-accredited animal-care programs and ISO 9001-based quality systems.
Tailored study design and execution covering target validation, hit-to-lead, lead optimization and preclinical efficacy/safety studies (PK/PD, DMPK, toxicology) using validated models, standardized readouts and electronic data management.
Whole-slide imaging, automated tissue processing, routine and customized staining (brightfield and fluorescence), quantitative digital analysis, algorithm-assisted scoring and secure cloud storage for pathology workflows.
Development and execution of immunoassays, multiplex biomarker panels, ELISAs, IHC, flow cytometry and high-content imaging assays for pharmacodynamic and translational analyses.
Program offering flexible access to laboratory infrastructure, vivarium space, equipment rental and dedicated scientific support to accelerate early-stage development for startups and academic spin-outs.
Translational support including gap analysis, product development planning, clinical trial readiness, trial management, regulatory submissions, medical writing, data management, statistics and pharmacovigilance provided through clinical partnerships.
Breeding, housing, genotyping, cryopreservation, rederivation and long-term storage of rodent lines under SPF conditions and FELASA guidance; services operate within AAALAC-accredited animal-care programs and ISO 9001-based quality systems.
Tailored study design and execution covering target validation, hit-to-lead, lead optimization and preclinical efficacy/safety studies (PK/PD, DMPK, toxicology) using validated models, standardized readouts and electronic data management.
Whole-slide imaging, automated tissue processing, routine and customized staining (brightfield and fluorescence), quantitative digital analysis, algorithm-assisted scoring and secure cloud storage for pathology workflows.
Development and execution of immunoassays, multiplex biomarker panels, ELISAs, IHC, flow cytometry and high-content imaging assays for pharmacodynamic and translational analyses.
Program offering flexible access to laboratory infrastructure, vivarium space, equipment rental and dedicated scientific support to accelerate early-stage development for startups and academic spin-outs.
Translational support including gap analysis, product development planning, clinical trial readiness, trial management, regulatory submissions, medical writing, data management, statistics and pharmacovigilance provided through clinical partnerships.
Expertise Areas
- Multisite preclinical contract research services (CRO)
- Neurology and behavioral neuroscience models
- Oncology modeling, organoid and PDX platforms
- Immunology, immune profiling and vaccine/mRNA testing
Key Technologies
- Patient-derived organoids (PDO) and tumoroids
- Patient-derived xenograft (PDX) models
- Automated high-throughput organoid screening
- Microphysiological systems / organ-on-chip
News & Updates
A strategic partnership to enable seamless access to multi-species expertise, focusing on advanced preclinical drug development and automated histopathology services.
A collaboration to remove barriers to drug development for PMS by providing accessible, industry-standard preclinical services.
Introduction of a new preclinical research model for Angelman Syndrome to support therapeutics development.
InnoSer to serve as the central hub for Kabuki Syndrome Foundation-funded preclinical research in a specific mouse model.
A strategic partnership to enable seamless access to multi-species expertise, focusing on advanced preclinical drug development and automated histopathology services.
A collaboration to remove barriers to drug development for PMS by providing accessible, industry-standard preclinical services.
Introduction of a new preclinical research model for Angelman Syndrome to support therapeutics development.
InnoSer to serve as the central hub for Kabuki Syndrome Foundation-funded preclinical research in a specific mouse model.